Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

First checkpoint inhibitor vaccine shown to be safe, effective in colon cancer animal model

A study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute described a potential therapeutic anticancer vaccine that frees suppressed cancer-killing immune cells, enabling them to attack and destroy a tumor.

23 Nov 2020

New model can predict the risk of adverse side effects of cancer treatment

The risk of serious adverse effects on the blood status and bone marrow of patients during chemotherapy can be predicted by a model developed at Linköping University, Sweden.

12 Nov 2020

MD Anderson presents positive clinical data from combination cancer therapies at SITC 2020

Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting & Pre-Conference Programs.

11 Nov 2020

High dose radiation therapy linked to shorter survival times in NSCLC patients

A genetic analysis of non-small cell lung cancer (NSCLC) patients on the phase III NRG Oncology RTOG 0617 clinical trial assessing radiation dose discovered that high dose radiation therapy is associated with shorter survival times among patients with a radiation-sensitive genotype in DNA repair pathway.

29 Oct 2020

Study finds persistence of racial disparities in treatment for common lung cancer

Lung cancer continues to be the most deadly solid cancer in the world, despite the fact that survival rates have been improving over the past decade.

28 Oct 2020

New tool can provide non-invasive decision support for NSCLC treatment

Personalized treatment options for patients with lung cancer have come a long way in the past two decades.

16 Oct 2020

New study may lead to more effective, personalized cancer immunotherapies

Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies.

12 Oct 2020

New initiative identifies key parameters underlying effective anti-tumor immunity

Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies.

9 Oct 2020

Potential drug treatment for AXL-low expressing EGFR-mutated lung cancer

Researchers at Kanazawa University report in Nature Communications the mechanism making some lung-cancer patients resistant to the drug osimertinib.

5 Oct 2020

Immunotherapy drug improves survival over standard chemotherapy for lung cancer patients

The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer (NSCLC), according to a new study led by Yale Cancer Center (YCC) researchers.

1 Oct 2020

Researchers identify a potential target for small cell lung cancer

The cover for issue 39 of Oncotarget features Figure 4, "Apoptosis assay of NRXN1-targeted ADC at IC50 dose calculated by growth inhibition curves," by Yotsumoto, et al. which reported that the authors identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1.

1 Oct 2020

Targeted therapy found to be effective at shrinking tumors in patients with nonsmall-cell lung cancer

An international team of researchers has found that selpercatinib, a drug that precisely targets cancers driven by mutations or alterations in the gene RET, was effective at shrinking tumours in patients with nonsmall cell lung cancer (NSCLC), with a majority of patients living for more than a year without disease progression.

28 Sep 2020

Sotorasib phase 1 trial shows encouraging anti-cancer activity in lung, colorectal cancers

A phase 1 clinical trial of sotorasib (AMG 510) in patients with heavily pretreated advanced solid tumors shows encouraging anti-cancer activity, especially in lung and colorectal cancers, reports a new study led by City of Hope and other renowned comprehensive cancer centers.

22 Sep 2020

Targeted therapy improves disease-free survival in patients with early-stage NSCLC

According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.

21 Sep 2020

Post-operative radiotherapy in NSCLC shows no statistically difference in 3-year disease-free survival

Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and after (neo) adjuvant chemotherapy shows no statistically significant difference in 3-year disease-free survival (DFS), according to data presented at ESMO 2020.

21 Sep 2020

KRASG12C inhibitor sotorasib shows durable clinical benefits for solid cancers

In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefits.

21 Sep 2020

Study finds wide variation in levels and anti-tumor effectiveness of a common cancer drug

When used to manage infections, the drug itraconazole is generally given at a single, fixed dose to all patients.

17 Sep 2020

UofL receives $11.5 million to accelerate the development of new immunotherapies

Cancer remains one of the most difficult and deadly challenges in human health, affecting Kentuckians at a higher rate than residents of any other state and killing more than 600,000 people each year in the U.S. alone.

14 Sep 2020

Suppressing tumor's growth and spread from the inside

A new technology that allows researchers to peer inside malignant tumors shows that two experimental drugs can normalize aberrant blood vessels, oxygenation, and other aspects of the tumor microenvironment in non-small cell lung cancer, helping to suppress the tumor's growth and spread, UT Southwestern researchers report.

3 Sep 2020

'Natural killer' cells could be a powerful weapon to fight against lung cancer

Immune cells called 'natural killer' (NK) cells could be a powerful weapon for fighting lung cancer, according to Australian researchers.

1 Sep 2020

Small Cell Lung Cancer News and Research

First checkpoint inhibitor vaccine shown to be safe, effective in colon cancer animal model

New model can predict the risk of adverse side effects of cancer treatment

MD Anderson presents positive clinical data from combination cancer therapies at SITC 2020

High dose radiation therapy linked to shorter survival times in NSCLC patients

Study finds persistence of racial disparities in treatment for common lung cancer

New tool can provide non-invasive decision support for NSCLC treatment

New study may lead to more effective, personalized cancer immunotherapies

New initiative identifies key parameters underlying effective anti-tumor immunity

Potential drug treatment for AXL-low expressing EGFR-mutated lung cancer

Immunotherapy drug improves survival over standard chemotherapy for lung cancer patients

Researchers identify a potential target for small cell lung cancer

Targeted therapy found to be effective at shrinking tumors in patients with nonsmall-cell lung cancer

Sotorasib phase 1 trial shows encouraging anti-cancer activity in lung, colorectal cancers

Targeted therapy improves disease-free survival in patients with early-stage NSCLC

Post-operative radiotherapy in NSCLC shows no statistically difference in 3-year disease-free survival

KRASG12C inhibitor sotorasib shows durable clinical benefits for solid cancers

Study finds wide variation in levels and anti-tumor effectiveness of a common cancer drug

UofL receives $11.5 million to accelerate the development of new immunotherapies

Suppressing tumor's growth and spread from the inside

'Natural killer' cells could be a powerful weapon to fight against lung cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News